These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 22203766)

  • 1. Potential utility of an expression array signature for predicting anthracycline responsiveness or resistance.
    Press MF; Gordon MA; Slamon DJ
    J Clin Oncol; 2012 Feb; 30(4):357-61. PubMed ID: 22203766
    [No Abstract]   [Full Text] [Related]  

  • 2. Multifactorial approach to predicting resistance to anthracyclines.
    Desmedt C; Di Leo A; de Azambuja E; Larsimont D; Haibe-Kains B; Selleslags J; Delaloge S; Duhem C; Kains JP; Carly B; Maerevoet M; Vindevoghel A; Rouas G; Lallemand F; Durbecq V; Cardoso F; Salgado R; Rovere R; Bontempi G; Michiels S; Buyse M; Nogaret JM; Qi Y; Symmans F; Pusztai L; D'Hondt V; Piccart-Gebhart M; Sotiriou C
    J Clin Oncol; 2011 Apr; 29(12):1578-86. PubMed ID: 21422418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Current status of epirubicin in the treatment of breast neoplasm].
    Jiang ZF; Song SC
    Zhonghua Zhong Liu Za Zhi; 2005 Apr; 27(4):193-5. PubMed ID: 15949413
    [No Abstract]   [Full Text] [Related]  

  • 4. Epirubicin approved for breast cancer treatment.
    Miller JL
    Am J Health Syst Pharm; 1999 Nov; 56(21):2177. PubMed ID: 10565690
    [No Abstract]   [Full Text] [Related]  

  • 5. Epirubicin in breast cancer: present and future.
    Levine M
    Clin Breast Cancer; 2000 Sep; 1 Suppl 1():S62-7. PubMed ID: 11970752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epirubicin as adjuvant therapy for breast cancer.
    Suh C
    Cancer Pract; 2001; 9(2):104-6. PubMed ID: 11879287
    [No Abstract]   [Full Text] [Related]  

  • 7. Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer.
    Knappskog S; Chrisanthar R; Løkkevik E; Anker G; Østenstad B; Lundgren S; Risberg T; Mjaaland I; Leirvaag B; Miletic H; Lønning PE
    Breast Cancer Res; 2012 Mar; 14(2):R47. PubMed ID: 22420423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epirubicin: is it like doxorubicin in breast cancer? A clinical review.
    Khasraw M; Bell R; Dang C
    Breast; 2012 Apr; 21(2):142-9. PubMed ID: 22260846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epirubicin as adjuvant therapy in breast cancer.
    Earl H; Iddawela M
    Expert Rev Anticancer Ther; 2004 Apr; 4(2):189-95. PubMed ID: 15056049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epirubicin hydrochloride.
    Dolbey C
    Clin J Oncol Nurs; 2002; 6(4):247-8. PubMed ID: 12087624
    [No Abstract]   [Full Text] [Related]  

  • 11. [Anthracycline induced cardiomyopathy in 51-years old women with breast cancer].
    Biskup P; Wozakowska-Kapłon B; Góźdź S
    Pol Arch Med Wewn; 2006 Jun; 115(6):551-8. PubMed ID: 17263227
    [No Abstract]   [Full Text] [Related]  

  • 12. Epirubicin for adjuvant therapy in node-positive breast cancer.
    Med Lett Drugs Ther; 2000 Feb; 42(1071):12-3. PubMed ID: 10725968
    [No Abstract]   [Full Text] [Related]  

  • 13. [Polychemotherapy versus monotherapy in metastatic breast carcinoma].
    Tanner J; Dunst J
    Strahlenther Onkol; 1999 Sep; 175(9):471. PubMed ID: 10518983
    [No Abstract]   [Full Text] [Related]  

  • 14. Role of carbonic anhydrase IX expression in prediction of the efficacy and outcome of primary epirubicin/tamoxifen therapy for breast cancer.
    Generali D; Fox SB; Berruti A; Brizzi MP; Campo L; Bonardi S; Wigfield SM; Bruzzi P; Bersiga A; Allevi G; Milani M; Aguggini S; Dogliotti L; Bottini A; Harris AL
    Endocr Relat Cancer; 2006 Sep; 13(3):921-30. PubMed ID: 16954440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Secreted cellular prion protein binds doxorubicin and correlates with anthracycline resistance in breast cancer.
    Wiegmans AP; Saunus JM; Ham S; Lobb R; Kutasovic JR; Dalley AJ; Miranda M; Atkinson C; Foliaki ST; Ferguson K; Niland C; Johnstone CN; Lewis V; Collins SJ; Lakhani SR; Al-Ejeh F; Möller A
    JCI Insight; 2019 Feb; 5(6):. PubMed ID: 30830863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer.
    Chrisanthar R; Knappskog S; Løkkevik E; Anker G; Østenstad B; Lundgren S; Berge EO; Risberg T; Mjaaland I; Maehle L; Engebretsen LF; Lillehaug JR; Lønning PE
    PLoS One; 2008 Aug; 3(8):e3062. PubMed ID: 18725978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating microRNA-451 as a predictor of resistance to neoadjuvant chemotherapy in breast cancer.
    Gu X; Xue JQ; Han SJ; Qian SY; Zhang WH
    Cancer Biomark; 2016; 16(3):395-403. PubMed ID: 27062696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined effect of epirubicin and lymphokine-activated killer cells on the resistant human breast cancer cells.
    Ozkan A; Ayhan A; Fiskin K
    Cell Biol Toxicol; 2004 Sep; 20(5):261-71. PubMed ID: 15685929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of epirubicin in advanced breast cancer.
    Conte PF; Gennari A; Landucci E; Orlandini C
    Clin Breast Cancer; 2000 Sep; 1 Suppl 1():S46-51. PubMed ID: 11970749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of dexverapamil plus anthracycline in patients with metastatic breast cancer who have progressed on the same anthracycline regimen.
    Warner E; Hedley D; Andrulis I; Myers R; Trudeau M; Warr D; Pritchard KI; Blackstein M; Goss PE; Franssen E; Roche K; Knight S; Webster S; Fraser RA; Oldfield S; Hill W; Kates R
    Clin Cancer Res; 1998 Jun; 4(6):1451-7. PubMed ID: 9626462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.